Research within the Diabetes theme is currently funded by Diabetes UK, the Juvenile Diabetes Research Foundation (USA), the European Foundation for the Study of Diabetes, BBSRC, the NHS R&D Fund, FP5/FP6 (EU), Interreg IIIIA, the Wellcome Trust and the South East England Development Agency. The translational relevance and clinical significance of work from the group is reflected in increased partnering with industrial collaborators, including Inotek Pharmaceuticals, GlaxoSmithKline, Astra-Zeneca and Medtronic, with scientific and clinical innovation from the group already significantly informing on the more effective treatment of patients with diabetes.
EU Funded Programmes:
1998 – 2002. EU Commission BIOMED 2 Concerted Action (Steering Committee Member - AJB) (530,000 ECU awarded to “Islet Research European Network [IREN]: Bioengineered cells for gene therapy of diabetes mellitus (18 Partners).
2004 – 2008. Coordination Action on the aetiology, pathology and prediction of type 1 diabetes in Europe (Project acronym: TONECA) (Workpackage Leader – AJB) EU Sixth Framework Programme Priority 1.1.1: Life Sciences, Genomics & Biotechnology for Health. (28 Partners; 1.2 million ECU awarded).
2006 – 2008. EU/INTERREG IIIA Programme: 1.9 million Euros awarded - Epidemiology, risk factors and new technology in coronary stenting. Partnership between Brighton (University of Brighton, BSUHT) and Lille (Centre Hospitalier, Universitaire de Lille). PI = SVM Investigation of poor prognostic outcome in diabetes patients undergoing angioplasty and stent deployment.
2011 – 2016. EU 7th FP Collaborative Project: 5.99 million Euros awarded – “PEVNET” Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes – an innovative research programme of biobanks and expertise (AJB together with Prof N.G. Morgan, Dr A.K. Foulis & 13 EU Partners)
2013 – 2016. EU 7th FP Collaborative Project: 4.8 million Euros awarded – “NEXT” Nano Engineering for Cross Tolerance: a new approach for bioengineered, vascularised, chimeric islet transplantation in non-immunosuppressed hosts (WM, AJB and MS & 4 EU Partners – HEI x1, SME x3)KTP (Knowledge Transfer Project) with GB Electronics, Worthing to develop medical diagnostic for identification of diabetic neuropathy. Collaboration with the School of Health Professions and Computing, Engineering and Mathematics Department. PI = AM
Funded research programmes from Scholl ( ReckettBenckeiser) to conduct a number of diabetes related projects and provide consultancy for the global diabetes foot care projects. PI = AM
Finance South East (SEEDA Investment Fund)
Novel treatment for diabetes by generation of insulin producing cell clusters. PI = WM
Technology output: Marriott, C.E., Harrison, M and Macfarlane W.M. (2008) Generation of insulin producing cell clusters using a novel cell culture system. UK Patent Number 0800524.1.
BBSRC CASE Studentship with Porvair Intl
Biomimetic 3D scaffolds for the cultivation and differentiation of stem cells. PI = WM
Technology output: Directed translation of research on polymer scaffolds into product development at Porvair International, UK funded by the Juvenile Diabetes Research Foundation (JDRF)
Research within the Diabetes theme is currently funded by Diabetes UK, the Juvenile Diabetes Research Foundation (USA), the European Foundation for the Study of Diabetes, BBSRC, the NHS R&D Fund, FP5/FP6 (EU), Interreg IIIIA, the Wellcome Trust and the South East England Development Agency.
The University of Brighton has been awarded £69,000 by Diabetes UK and the National Kidney Research Fund